Dose‐response curves of blood pressure and of the biochemical components of the renin‐
angiotensin‐aldosterone system were determined during long‐term treatment with captopril …

The introduction of captopril-the first orally active inhibitor of angiotensin converting enzyme-
into clinical medicine has been an example of skilled, purposeful pharmacological …

The effects of hydralazine (3 mg/kg) and the angiotensin 1-converting enzyme (ACE)
inhibitor captopril (SQ 14,225)(100 mg/kg) on mean arterial blood pressure, plasma renin …

Eight hypertensive patients with normal renal function and receiving diuretic therapy for at
least 28 days received captopril in small increasing doses (6.25, 12.5, and 25 mg). Supine …

1. Captopril was shown to be as effective as hydrochlorothiazide in lowering the blood
pressure in patients with moderately severe essential hypertension. 2. With the combination …

Randomised, double-blind cross-over trials were performed in seven anephric patients to
determine the effect of the orally active angiotensin-converting enzyme inhibitor captopril on …

1. The peptide converting enzyme inhibitor captopril was given (1· 25 mg/kg intravenously)
to normal and nephrectomized rats and rats with renovascular and deoxycorticosterone …

Captopril, an inhibitor of angiotensin converting enzyme, was administered twice daily to 13
hypertensive patients for a mean period of 9 weeks. Continuous blood pressure control in …

Captopril, a specific oral inhibitor of angiotensin-converting enzyme, was given to 18
unselected patients with moderate essential hypertension. Mean blood pressure fell by …

Captopril lowers blood pressure without increasing heart rate and plasma norepinephrine,
which suggests that this drug may potentiate arterial baroreflexes. In eight subjects with …